Latest stories on EWTX
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
PR Newswire50 · neutralgeneral
Edgewise Therapeutics price target raised to $60 from $53 at JPMorgan
The Fly63 · neutralanalyst
Edgewise Therapeutics: The Servier Deal Creates A Self-Funded Cardiovascular Platform
Seeking Alpha73 · bullishproduct/pr
Edgewise Therapeutics price target raised to $36 from $32 at Goldman Sachs
The Fly61 · neutralanalyst
Edgewise Therapeutics GAAP EPS of -$0.53
Seeking Alpha34 · bearishearnings
Edgewise Therapeutics, Inc. (EWTX) files 8-K
SEC 8-K50 · neutralgeneral
Edgewise Therapeutics Reports Second Quarter 2026 Financial Results
PR Newswire73 · bullishearnings
8-K/A - Edgewise Therapeutics, Inc. (EWTX) files 8-K
SEC 8-K50 · neutralgeneral
Edgewise Therapeutics Sells Muscular Dystrophy Assets to Servier
TipRanks52 · neutralgeneral
Edgewise Therapeutics, Inc. (EWTX) files 8-K
SEC 8-K50 · neutralgeneral
Servier finalise l'acquisition de l'activité dystrophie musculaire d'Edgewise Therapeutics
PR Newswire62 · neutralm&a
Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business
PR Newswire62 · neutralm&a
Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules
PR Newswire50 · neutralgeneral
Is Edgewise Therapeutics, Inc. (EWTX) A Good Stock To Buy Now?
Yahoo Top57 · neutralanalyst
Edgewise Therapeutics, Inc. (EWTX) Price Target Raised to $59 on Positive HCM Trial Data
Yahoo Top67 · bullishanalyst
Edgewise Therapeutics, Inc. (EWTX) Discusses Top Line Data From EDG-7500 Phase II CIRRUS-HCM Trial in Hypertrophic Cardiomyopathy Transcript
Seeking Alpha56 · neutralproduct/pr
Edgewise Bounds Between Double-Digit Losses And Gain — What's Going On?
Investors.com48 · neutralgeneral
Edgewise falls after trial data for heart disease therapy
Seeking Alpha34 · bearishearnings
EDG-7500 Shows Consistent Efficacy and Safety Across Obstructive and Nonobstructive HCM in Phase 2 CIRRUS-HCM Data
MarketChameleon73 · bullishproduct/pr
Edgewise Therapeutics, Inc. (EWTX) files 8-K
SEC 8-K50 · neutralgeneral
Edgewise: 'Buy' On Muscular Dystrophy Program Sale And EDG-7500 Advancement
Seeking Alpha67 · bullishproduct/pr